As­traZeneca hands off epilep­sy pro­grams to Ovid; Amy­lyx scores pri­or­i­ty re­view for ALS drug 

Still re­cov­er­ing from a set­back in its lead pro­gram, Ovid Ther­a­peu­tics has turned to As­traZeneca for a suite of ex­per­i­men­tal epilep­sy drugs.

Ovid is pay­ing the Big Phar­ma part­ner $5 mil­lion in cash and $7.5 mil­lion in stock to ac­cess a li­brary of ear­ly-stage small mol­e­cules tar­get­ing the KCC2 trans­porter, in­clud­ing lead can­di­date OV350. As­traZeneca stands to re­ceive mile­stones adding up to more than $200 mil­lion and re­tains an op­tion for a strate­gic col­lab­o­ra­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.